| P50 | author | Antonio Lanzavecchia | Q4776729 |
| | Jacques Simpore | Q34176386 |
| | Giampietro Corradin | Q80329128 |
| | Janine Stubbs | Q111535316 |
| P2093 | author name string | Balam Saidou | |
| | Sope Olugbile | |
| P2860 | cites work | Genome sequence of the human malaria parasite Plasmodium falciparum | Q22122524 |
| | Rapid identification of malaria vaccine candidates based on alpha-helical coiled coil protein motif | Q28469255 |
| | Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. | Q33305467 |
| | Sequence conservation in Plasmodium falciparum alpha-helical coiled coil domains proposed for vaccine development | Q33459259 |
| | The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria | Q33512926 |
| | Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response | Q33613937 |
| | A defunctioning polymorphism in FCGR2B is associated with protection against malaria but susceptibility to systemic lupus erythematosus | Q33842644 |
| | Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1 | Q33870167 |
| | Antibody responses to infections with strains of Plasmodium falciparum expressing diverse forms of merozoite surface protein 2. | Q34006002 |
| | Specificity of the protective antibody response to apical membrane antigen 1 | Q34007362 |
| | In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response | Q34260615 |
| | An epitope recognised by inhibitory monoclonal antibodies that react with a 51 kilodalton merozoite surface antigen in Plasmodium falciparum | Q35096341 |
| | Systemic lupus erythematosus-associated defects in the inhibitory receptor FcgammaRIIb reduce susceptibility to malaria. | Q35758478 |
| | Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies | Q36227228 |
| | Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning | Q36459907 |
| | Antigenic differences and conservation among placental Plasmodium falciparum-infected erythrocytes and acquisition of variant-specific and cross-reactive antibodies | Q36789977 |
| | Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity | Q36943252 |
| | Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness | Q37099503 |
| | Relationship between human immunodeficiency virus type 1 coinfection, anemia, and levels and function of antibodies to variant surface antigens in pregnancy-associated malaria | Q37116542 |
| | Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated Plasmodium falciparum protein PFF0165c | Q37451071 |
| | Strain-specific humoral response to a polymorphic malaria vaccine | Q37582833 |
| | Natural selection on polymorphic malaria antigens and the search for a vaccine | Q38952188 |
| | Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria | Q39247931 |
| | High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya | Q39362550 |
| | Protective immunization with invariant peptides of the Plasmodium falciparum antigen MSA2. | Q39433305 |
| | Fcgamma receptor-mediated phagocytosis of Plasmodium falciparum-infected erythrocytes in vitro. | Q39515245 |
| | Plasmodium falciparum: a major role for IgG3 in antibody-dependent monocyte-mediated cellular inhibition of parasite growth in vitro | Q39515257 |
| | Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass | Q39823427 |
| | Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen | Q40091335 |
| | Epidemiological correlation between levels of antibodies promoting merozoite phagocytosis of Plasmodium falciparum and malaria-immune status | Q40162910 |
| | A novel antibody-dependent cellular cytotoxicity mechanism involved in defense against malaria requires costimulation of monocytes FcgammaRII and FcgammaRIII. | Q40168745 |
| | Cooperation between antibodies and monocytes that inhibit in vitro proliferation of Plasmodium falciparum | Q40183845 |
| | Enhanced Plasmodium falciparum merozoite phagocytosis by monocytes from immune individuals | Q40613128 |
| | High oxygen radical production is associated with fast parasite clearance in children with Plasmodium falciparum malaria | Q40639357 |
| | Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages | Q41835030 |
| | Structural and antigenic polymorphism of the 35- to 48-kilodalton merozoite surface antigen (MSA-2) of the malaria parasite Plasmodium falciparum | Q41851051 |
| | Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes | Q42938913 |
| | Fcgamma receptor IIa (CD32) polymorphism is associated with protection of infants against high-density Plasmodium falciparum infection. VII. Asembo Bay Cohort Project | Q43634113 |
| | Functional characterization of the antibody-mediated protection against blood stages of Plasmodium falciparum in the monkey Saimiri sciureus | Q43872696 |
| | Inhibition of in vitro growth of plasmodium falciparum field isolates mediated by human antibodies to Pf155/RESA and Pf332. | Q43935070 |
| | Geographical patterns of allelic diversity in the Plasmodium falciparum malaria-vaccine candidate, merozoite surface protein-2. | Q43951122 |
| | 46-53 kilodalton glycoprotein from the surface of Plasmodium falciparum merozoites | Q44542427 |
| | Association of Fcgamma receptor IIa (CD32) polymorphism with severe malaria in West Africa. | Q46158460 |
| | Plasmodium falciparum: a rapid technique for genotyping the merozoite surface protein 2. | Q46226747 |
| | Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria | Q46227346 |
| | Opsonization as an effector mechanism in human protection against asexual blood stages of Plasmodium falciparum: Functional role of IgG subclasses | Q46370720 |
| | Fc receptor but not complement binding is important in antibody protection against HIV. | Q46545827 |
| | IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. | Q47830190 |
| | Differential effect and interaction of monocytes, hyperimmune sera, and immunoglobulin G on the growth of asexual stage Plasmodium falciparum parasites | Q47843178 |
| | Mice immunised with synthetic peptide from N-terminal conserved region of merozoite surface antigen-2 of human malaria parasite Plasmodium falciparum can control infection induced by Plasmodium yoelii yoelii 265BY strain | Q47856201 |
| | Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum | Q47864459 |
| | Cross-reactivity of antibody against an epitope of the Plasmodium falciparum second merozoite surface antigen | Q47888814 |
| | Anti-MSP1 block 2 antibodies are effective at parasite killing in an allele-specific manner by monocyte-mediated antibody-dependent cellular inhibition | Q47897203 |
| | A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea | Q47901914 |
| | Bacterially expressed and refolded receptor binding domain of Plasmodium falciparum EBA-175 elicits invasion inhibitory antibodies. | Q47910023 |
| | Fcgamma receptor IIA and IIIB polymorphisms are associated with susceptibility to cerebral malaria | Q47917458 |
| | An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus | Q47957009 |
| | Plasmodium falciparum strain-specific antibody blocks binding of infected erythrocytes to amelanotic melanoma cells | Q47976611 |
| | Induction of crisis forms in the human malaria parasite Plasmodium falciparum by gamma-interferon-activated, monocyte-derived macrophages | Q47982109 |
| | Opsonic activity of human immune serum on in vitro phagocytosis of Plasmodium falciparum infected red blood cells by monocytes | Q47993075 |
| | Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial | Q48034345 |
| | Sequence comparison of allelic forms of the Plasmodium falciparum merozoite surface antigen MSA2. | Q48246648 |
| | Structural diversity in the 45-kilodalton merozoite surface antigen of Plasmodium falciparum | Q48273602 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Plasmodium falciparum | Q311383 |
| | antibody | Q79460 |
| P304 | page(s) | 1143-1152 | |
| P577 | publication date | 2010-12-28 | |
| P1433 | published in | Infection and Immunity | Q6029193 |
| P1476 | title | Strain-transcending Fc-dependent killing of Plasmodium falciparum by merozoite surface protein 2 allele-specific human antibodies | |
| P478 | volume | 79 | |